2025 NMD4C and MDC Neuromuscular Fellowship Funding Competition Opens
Together with Muscular Dystrophy Canada (MDC) we are excited to announce the opening of our 2025 annual funding competition to award postdoctoral fellowships in neuromuscular disease (NMD) research, and clinical fellowship awards in neuromuscular medicine and electromyography!
This annual funding competition provides salary support for early-career scientists to conduct postdoctoral studies in a laboratory focused on research of NMDs, and early-career clinicians to participate in a neuromuscular medicine and electromyography fellowship training program.
Successful applicants are eligible to receive $40 000 in funding over a one-year period for a postdoctoral fellowship, and $80 000 in funding over a one-year period for a clinical fellowship. This year, we will fund two (2) postdoctoral research fellowships and two (2) clinical fellowships.
Dates and Timelines
Funding competition opens: September 3rd, 2024
Application submission deadline: October 15th, 2024.
Eligibility and Selection Criteria
Eligibility and selection guidelines are available on the NMD4C website for both the postdoctoral research fellowship and clinical fellowships, and instructions on how to submit your application.
Postdoctoral fellowship competition guidelines
Clinical fellowship competition guidelines
If you have any questions about the 2025 competition, please contact network manager Erin Beattie at .
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.